炭疽ワクチンの世界市場 - 市場規模：製品タイプ別、用途別、エンドユーザー別、地域別、予測

炭疽ワクチンの市場規模と予測

炭疽ワクチンの市場規模は、2024年に131億7,000万米ドルと評価され、2026年から2032年にかけてCAGR 5.59%で成長し、2032年には292億7,000万米ドルに達すると予測されています。

炭疽の流行の高まりにより、炭疽ワクチンの世界市場は急速に成長しています。炭疽ワクチンの市場は、罹患動物の加熱不十分な肉や生肉の消費の増加によって牽引されています。また、皮や毛織物のような汚染された商品の工業的または製造的加工の増加も市場の成長に寄与します。炭疽ワクチンの世界市場レポートでは、市場の全体的な評価を提供します。主要セグメント、動向、市場促進要因、抑制要因、競合情勢、市場で重要な役割を果たしている要因などを包括的に分析しています。

炭疽ワクチンの世界市場定義

炭疽は、炭疽菌によって引き起こされる危険な感染症です。これを回避するワクチン接種があります。しかし、このワクチン接種は通常、一般の人々には提供されていません。炭疽菌に感染する危険性の高い人、あるいはすでに炭疽菌に暴露された人にのみ適応されます。炭疽はグラム陽性菌である炭疽菌の芽胞によって引き起こされる重篤な感染症です。肺、腸、皮膚、注射の4つが主な感染経路です。ヒトも動物も炭疽菌に感染しやすく、特にウシ、ヒツジ、ヤギ、ウマなどの反芻動物に感染しやすいです。炭疽菌は個体から個体へ感染することは困難です。

炭疽の症状や徴候は感染のタイプによって異なります。皮膚炭疽、消化器炭疽、吸入炭疽、注射炭疽では症状が異なります。消化器炭疽の最も一般的な症状は、吐き気、腹痛、食欲不振、嘔吐、発熱、血性下痢、首の腫れ、頭痛、嚥下困難などです。吸入性炭疽では、息切れ、咳に血が混じる、飲み込みにくい、軽い胸部不快感、吐き気などが起こる。注射炭疽の最も一般的な徴候と症状は、多臓器不全、髄膜炎、注射部位周辺の発赤です。

現在、世界的に行われている炭疽の診断法は、患者の血液検体中の抗体や毒素の有無によるものです。さらに医療専門家は、炭疽菌の存在を診断するために直接検査を行うことを勧めています。炭疽菌の予防接種には無細胞型と生ワクチン型があります。炭疽菌の予防接種の主な理由は、吸入による感染の危険性です。暴露前ワクチンとして、炭疽毒素成分を含み、3～6回の接種で防御免疫を獲得する無細胞ワクチン（炭疽ワクチン吸着型、AVA）が使用されます。沈降炭疽ワクチン（AVP）は、初回接種時に3回接種し、6ヵ月後にブースター接種を行う。ブースター用量は、防御免疫を誘発し維持するために12ヶ月に1回必要です。

現在の炭疽ワクチン接種は局所および全体的な反応原性（紅斑、硬結、疼痛、発熱）が高いです。予防接種の約1％に重篤な副作用があります。組換え生ワクチンと組換えサブユニットワクチンは、現在開発中の2つの新しい第2世代ワクチンです。炭疽ワクチン吸着型（AVA）またはバイオスラックス（BioThraxTM）は、認可された唯一の炭疽ワクチンであり、炭疽菌に暴露されるリスクが高い18歳から65歳の人に対する、炭疽菌による疾病予防のための積極的なワクチン接種が推奨されています。ミシガン州ランシングにあるEmergent BioDefense Operations Lansing Inc.が1970年以来ワクチン製造の認可を受けています。複数の企業が次世代の炭疽ワクチン製造に取り組んでいます。

世界の炭疽ワクチン市場概要

炭疽菌の発生が増加しているため、炭疽ワクチン市場は急成長しています。世界市場の主な促進要因は、感染動物の生肉や加熱不十分な肉を食べることの人気の上昇です。さらに、毛織物や皮革のような汚染された動物用品の商業的・工業的加工が大幅に増加していることも、市場の成長を後押ししています。炭疽菌は、野生の野生動物や家畜に最もよく見られます。世界中で畜産が盛んになるにつれ、農場の数は増加しています。農場で働くと、人々は動物の近くにいることになり、炭疽菌に感染する危険性があります。この要素が市場の主要な原動力となっています。

一方、炭疽に対する自主的なスクリーニングの割合が低いことは、炭疽ワクチン市場にとって大きな障害となる可能性があります。さらに、アフリカのような地域では、炭疽菌診断検査に関する理解が不足しているため、企業が顧客に直接アプローチすることが難しく、市場の成長を阻害しています。炭疽菌の有病率の上昇や、加熱不十分な肉や生肉の消費拡大といった要因が、市場拡大の主な原因となっています。診断、サーベイランス、アウトブレイク対応を改善することで、動物でもヒトでも回避できる可能性があります。この病気は有病率が高く、感染のリスクと重大性から、予防医療機関にとって最優先事項のひとつとなっています。

炭疽菌は、感染した食肉によって動物から発見されています。鶏肉、牛肉、豚肉の消費パターンは大きく異なりますが、いずれも炭疽のリスクを高めます。以上のことから、炭疽ワクチン市場は予測期間中に拡大する可能性が高いです。同市場は少数のプレーヤーによって支配されており、予測期間中に発展する可能性が高いですが、診断およびスクリーニング検査に関する認識不足や炭疽ワクチンの法外なコストといった要因が市場拡大の妨げになる可能性があります。

目次

第1章 世界の炭疽ワクチン市場のイントロダクション

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 炭疽ワクチンの世界市場展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 炭疽ワクチンの世界市場：製品タイプ別

• 概要
• 無細胞PAワクチン
  • AVA
  • AVP
• 生細胞

第6章 炭疽ワクチンの世界市場：用途別

• 概要
• ヒト用
• 動物用

第7章 炭疽ワクチンの世界市場：エンドユーザー別

• 概要
• 病院薬局
• 小売薬局
• その他

第8章 炭疽ワクチンの世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋地域
• 世界のその他の地域
  • ラテンアメリカ
  • 中東・アフリカ

第9章 世界の炭疽ワクチン市場の競合情勢

• 概要
• 各社の市場ランキング
• 主な開発戦略

第10章 企業プロファイル

• Zoetis Inc.
• Emergent Bio-Solutions
• Merck & Co. Inc.
• Colorado Serum
• PharmaAthene Inc.
• Vecol
• Biogenesis Bago Inc.
• Porton Biopharma Inc.
• Merial
• Intervac

第11章 主な発展

• 製品上市／開発
• 合併と買収
• 事業拡大
• パートナーシップと提携

第12章 付録

• 関連調査

Anthrax Vaccines Market Size And Forecast

Anthrax Vaccines Market size was valued at USD 13.17 Billion in 2024 and is projected to reach USD 29.27 Billion by 2032, growing at a CAGR of 5.59 % during the forecast period 2026-2032.

Because of the rising prevalence of the disease, the global market for anthrax vaccinations is rapidly growing. The market for anthrax vaccinations is driven by the increased consumption of undercooked or raw meat from diseased animals. Increased industrial or manufacturing processing of contaminated commodities like skins and hair wool will also help to grow the market. The Global Anthrax Vaccines Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Anthrax Vaccines Market Definition

Anthrax is a dangerous infection caused by the bacteria Bacillus anthracis. There is a vaccination that can help avoid it. This vaccination, however, is not normally available to the general population. It is only indicated for persons who are at a high risk of contracting B. anthracis or who have already been exposed to it. Anthrax is a serious infectious disease caused by the spores of Bacillus anthracis, a gram-positive bacterium. The lungs, intestines, skin, and injectables are the four main routes of infection. Both humans and animals are susceptible to anthrax, particularly ruminants like cattle, sheep, goats, and horses. It is difficult to spread from one individual to another.

Anthrax symptoms and signs differ based on the type of infection. The symptoms of cutaneous anthrax, gastrointestinal anthrax, inhalation anthrax, and injectable anthrax differ. The most common signs and symptoms of gastrointestinal anthrax include nausea, abdominal pain, lack of appetite, vomiting, fever, bloody diarrhea, swelling neck, headache, and difficulty swallowing. Inhalation anthrax causes shortness of breath, blood in the cough, uncomfortable swallowing, minor chest discomfort, and nausea. The most common indications and symptoms of injectable anthrax are multiple organ failure, meningitis, and redness around the injection site.

Currently, the primary approaches in the diagnosis of anthrax available worldwide rely on the presence or absence of antibodies or toxins in a patient's blood sample. Furthermore, healthcare professionals advised using direct testing to diagnose the presence of Bacillus anthracis. Anthrax vaccinations are available in both cell-free and live forms. The main reason for anthrax immunization is the danger of infection through inhalation. An acellular vaccine (anthrax vaccine adsorbed or AVA), which contains anthrax toxin components and results in protective immunity after 3 to 6 doses, is used as a pre-exposure vaccine. Anthrax vaccine precipitated (AVP) is given in three doses at prime vaccination, with a booster dose 6 months later. A booster dose is required once every 12 months to elicit and sustain protective immunity.

Current anthrax vaccinations have a high level of local and overall reactogenicity (erythema, induration, soreness, fever). About 1% of immunizations have serious side effects. Recombinant live vaccines and recombinant sub-unit vaccines are the two new second-generation vaccines that are currently in development. Anthrax Vaccine Adsorbed (AVA) or BioThraxTM, the only licensed anthrax vaccine, is recommended for active vaccination for the prevention of disease caused by Bacillus anthracis in those aged 18 to 65 who are at a high risk of exposure. Emergent BioDefense Operations Lansing Inc. in Lansing, Michigan, has been licensed to manufacture the vaccine since 1970. Multiple companies are working on next-generation anthrax vaccinations.

Global Anthrax Vaccines Market Overview

Because of the rising occurrence of anthrax, the Anthrax Vaccines Market is fast growing. A major driver of the global market is the rise in popularity of eating raw and undercooked meat from infected animals. Furthermore, a large increase in the commercial and industrial processing of contaminated animal commodities such as hair wool, and hide boosted the market growth. Anthrax is most commonly seen in wild wildlife and livestock. The number of farms is growing as animal husbandry becomes more popular around the world. Working on farms puts people in close proximity to animals, putting them at risk of contracting anthrax. This element operates as the market's primary driving force.

The low percentage of voluntarily screening for anthrax disease, on the other hand, could be a major impediment to the Anthrax Vaccines Market. Furthermore, in places like Africa, a lack of understanding regarding anthrax diagnostic tests makes it difficult for companies to reach out directly to their clients, stifling market growth. Factors such as the rising prevalence of anthrax and the expanding consumption of undercooked or raw meat are mostly to blame for the market's expansion. It may be possible to avoid it in both animals and humans by improving diagnosis, surveillance, and outbreak response. The disease has a high prevalence rate, and the risk and severity of infection make it one of the top priorities for preventive healthcare organizations.

Anthrax has been found in animals as a result of infected meat. Although the consumption patterns in chicken, beef, and pork are substantially different, they all raise the risk of anthrax. As a result of the foregoing, the Anthrax Vaccines Market is likely to expand over the forecast period. Although the market is dominated by a few players and is likely to develop over the forecast period, factors such as a lack of awareness regarding diagnostic and screening tests and the anthrax vaccine's exorbitant cost may hinder market expansion.

Global Anthrax Vaccines Market Segmentation Analysis

The Global Anthrax Vaccines Market is segmented based on Product Type, Application, End-User, And Geography.

Based on the Product Type, the market is bifurcated into Cell-Free PA Vaccines and Live Cells. Cell-Free PA Vaccines are expected to hold the largest market share in the coming years.

Anthrax Vaccines Market, By Application

• Animal Use
• Human UseBased on Application, the market is bifurcated into Animal Use And Human Use. The animal use anthrax vaccination segment is expected to dominate the market. Anthrax is an epizootic disease that spreads from animals to humans and appears in sensitive animals, both wild and domesticated, on a regular basis. Anthrax is acute septicemia with a high fatality rate in herbivore animals such as cattle, sheep, goats, camels, and antelopes. It is generally accompanied by hemorrhagic lymphadenitis. In dogs, pigs, and horses, however, it is a less severe but possibly lethal condition.

Anthrax Vaccines Market, By End-User

• Hospital Pharmacy
• Retail pharmacy
• Others

Based on End-User, the market is bifurcated into Hospital Pharmacy, Retail pharmacy, and Others. Hospital pharmacies dominated the market. Hospitals serve as a key immunization venue, which explains why anthrax vaccine sales are so high there. Anthrax vaccines are, additionally, routinely administered to patients in hospitals.

Anthrax Vaccines Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world
• On the basis of Geography, the Global Anthrax Vaccines Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. The largest share in the market will be dominated by North America owing to the growing number of anthrax patients.

Key Players

The "Global Anthrax Vaccines Market" study report will provide a valuable insight with an emphasis on global market including some of the major players such as Zoetis Inc., Emergent Bio-Solutions, Merck & Co. Inc., Colorado Serum, PharmaAthene Inc., Vecol, Biogenesis Bago Inc., Porton Biopharma Inc., Merial, and Intervac.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share and market ranking analysis of the above-mentioned players globally.

Key Developments

• In August 2020, Anthim (obiltoxaximab for injection), a monoclonal antibody (mAb) anthrax antitoxin, developed by Elusys Therapeutics Inc. (Elusys), obtained approval from Health Canada for the treatment of inhalation anthrax and can be used to treat post-exposure prophylaxis in both adults and children.
• In August 2020, Dr. Jamie Benn Felix and the Cook Wildlife Lab team from Texas A&M University College of Veterinary Medicine & Biomedical Sciences performed pilot research for the first oral anthrax vaccine for livestock (CVMBS).

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL ANTHRAX VACCINES MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL ANTHRAX VACCINES MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL ANTHRAX VACCINES MARKET, BY PRODUCT TYPE

• 5.1 Overview
• 5.2 Cell-Free PA Vaccines
  • 5.2.1 Anthrax Vaccine Adsorbed (AVA)
  • 5.2.2 Anthrax Vaccine Precipitated (AVP)
• 5.3 Live Cells

6 GLOBAL ANTHRAX VACCINES MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Human Use
• 6.3 Animal Use

7 GLOBAL ANTHRAX VACCINES MARKET, BY END-USER

• 7.1 Overview
• 7.2 Hospital Pharmacy
• 7.3 Retail pharmacy
• 7.4 Others

8 GLOBAL ANTHRAX VACCINES MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East & Africa

9 GLOBAL ANTHRAX VACCINES MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 Zoetis Inc.
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Emergent Bio-Solutions
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Merck & Co. Inc.
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Colorado Serum
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 PharmaAthene Inc.
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Vecol
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 Biogenesis Bago Inc.
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 Porton Biopharma Inc.
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 Merial
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 Intervac
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments

11 KEY DEVELOPMENTS

• 11.1 Product Launches/Developments
• 11.2 Mergers and Acquisitions
• 11.3 Business Expansions
• 11.4 Partnerships and Collaborations

12 Appendix

• 12.1 Related Research